Microcap Ledger RenovoRx, Inc. $RNXT
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Mountain View, CA
- Fiscal year end
- December 31
- Shares outstanding
- 45,129,508 [10-Q 2026-08-13]
What the company doesAI summary of filing
RenovoRx is a clinical-stage and commercial-stage life sciences company developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared local drug-delivery device. The company's patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform delivers chemotherapy across the arterial wall near tumor sites to minimize toxicities compared to systemic intravenous therapy. RenovoRx generated $1.1 million in revenue from RenovoCath device sales in 2025 from U.S. cancer centers, and is actively enrolling patients in its Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath for treatment of locally advanced pancreatic cancer, with final data anticipated in 2027. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.47M | −$6.43M | −$6.58M | $9.48M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $1.12M | −$11.17M | −$10.97M | $7.02M | [10-K 2026-03-30] |
| FY ended Dec 2024 | $43.0K | −$8.81M | −$9.13M | $7.15M | [10-K 2026-03-30] |
- Quarterly cash burn
- −$3.29M
- Cash runway Estimate
- ~8.6 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 24,001,339 | [10-Q 2024-11-13] |
| 2025-03-25 | 36,546,752 | [10-K 2025-04-01] |
| 2025-05-09 | 36,572,232 | [10-Q 2025-05-15] |
| 2025-08-11 | 36,645,884 | [10-Q 2025-08-14] |
| 2025-11-12 | 36,649,916 | [10-Q 2025-11-13] |
| 2026-03-23 | 45,052,706 | [10-K/A 2026-05-15] |
| 2026-05-07 | 45,099,133 | [10-Q 2026-05-14] |
| 2026-08-07 | 45,129,508 | [10-Q 2026-08-13] |
- Shelf registration
- S-3 filed 2026-04-16; declared effective 2026-04-27 [S-3 2026-04-16]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-07-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-02] |
| 2026-01-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-02] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-10 | Voll Mark | grant | 80,000 | — | [4 2026-09-15] |
| 2026-05-19 | Voll Mark | buy | 25,000 | $0.79 | [4 2026-05-21] |
| 2022-04-22 | Ryan Una S | other | 26,838 | $0.93 | [4 2026-06-24] |
| 2022-04-22 | Ryan Una S | other | 16,206 | $1.62 | [4 2026-06-24] |
| 2022-03-03 | Ryan Una S | other | 47,789 | $4.19 | [4 2026-06-24] |
| 2022-03-03 | Ryan Una S | other | 6,332 | $3.95 | [4 2026-06-24] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-20 | 8-K | Other events |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-04 | 8-K | Other events |
| 2026-07-02 | 8-K | Listing notice or transfer |
| 2026-06-30 | 8-K | Shareholder vote results |
| 2026-05-15 | 10-K/A | Amended report |
| 2026-05-14 | 10-Q | Quarterly report |
| 2026-05-14 | 8-K | Results of operations |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-27 | 424B3 | Prospectus or prospectus supplement |
| 2026-04-27 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $RNXT
Email me when RenovoRx, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.